Oncology

Connect with us

A revolution in cancer drug development

Recent developments in cancer immunotherapy illustrate virtually unprecedented clinical benefit in some advanced cancer patients, and the potential for cure seems tangible. In line with transforming patient care, we have also already begun to transform drug development.

Given the sheer number of investigational agents and potential combination cancer immunotherapies before us, the opportunity to make a major impact on the world’s cancer burden and on patient’s lives has never been greater.

Therapeutic and indication experience you can trust

Two thirds of the oncology studies we conduct are in early phase. We have successfully operationalised alternative study designs such as the New Continuous Reassessment Method (nCRM). Our experience extends to managing some of the largest global phase III registration studies.

We have conducted almost 80 immuno-oncology studies, many complemented by sophisticated adaptive designs. This includes using innovative ACT technologies in the oncology development space.

Flexible models to meet your needs

We have a diverse customer base, giving us vast experience in managing the spectrum of client needs. Whether you are a large organisation that needs an end to end solution or a small biotech requiring advice and support for proof of concept, we can provide a solution that works for you.